Scholarlink

Background <p>Heart failure (HF) presents a significant global health challenge, caused by mitochondrial dysfunction, oxidative stress, and chronic inflammation, all of which impair cardiac function. This investigation introduces a new nanoplatform, PCM-refined M2 macrophage membrane-coated CeO<sub>2</sub> nanozyme loaded with PGAM5 siRNA (P-MM@Ps-CeO<sub>2</sub>), that can target these interconnected disease pathways.</p> Results <p>Mechanistically, silencing PGAM5 with this nanoplatform precludes the dephosphorylation of Drp1 at Ser637, thereby lessening excessive mitochondrial fission. Yet, it restores the DDX17- BCL6 control mechanism to decrease Drp1 levels, ultimately maintaining mitochondrial balance. CeO<sub>2</sub> nanozymes break down reactive oxygen species (ROS), Attenuating cellular oxidative imbalance, while M2 macrophage membranes improve anti-inflammatory targeting to inflamed heart tissue, with PCM ensuring delivery precisely to the heart. In vitro, P-MM@Ps-CeO<sub>2</sub> re-established baseline 90% of the viability in lipopolysaccharide- worsened HL-1 cardiomyocytes, attenuated ROS by 70%, and lowered Pro-inflammatory cytokines (IL-1β, TNF-α) by up to 67%. It also preserved mitochondrial integrity, increased ATP production, and lowered apoptosis by 70%. In vivo, in a doxorubicin-induced HF mouse model, the nanoplatform improved ejection fraction to 65% and fractional shortening to 35%, reduced myocardial fibrosis by 30% and apoptosis by 70%, and increased cardiac accumulation by 2.5 times.</p> Conclusions <p>These outcomes indicate that P-MM@Ps-CeO₂ transcends conventional HF interventions, which typically fail to address mitochondrial abnormalities. The nanoplatform showed excellent biocompatibility, with minimal hemolytic activity and no detectable organ toxicity, supporting its potential for clinical use. By simultaneously targeting mitochondrial turnover, reactive oxygen species (ROS) stress, and inflammation, P-MM@Ps-CeO<sub>2</sub> yields an advantageous pioneering treatment modality, HF, highly capable of improving analysis outcomes for the worldwide HF cohort.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A multifunctional biomimetic nanoplatform targeting mitochondrial dynamics and oxidative stress for heart failure therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月25日

查看全文
  • Ming Fang,
  • Alimujiang Maimaitijiang,
  • Limin Fan,
  • Yixin Liu,
  • Wei Wang,
  • Xiangdong Meng,
  • Jingyi Cao,
  • Lin Shen,
  • Bing Deng,
  • Wang Zheng,
  • Fanglin Lu,
  • Yu Zhuang

摘要

Background

Heart failure (HF) presents a significant global health challenge, caused by mitochondrial dysfunction, oxidative stress, and chronic inflammation, all of which impair cardiac function. This investigation introduces a new nanoplatform, PCM-refined M2 macrophage membrane-coated CeO2 nanozyme loaded with PGAM5 siRNA (P-MM@Ps-CeO2), that can target these interconnected disease pathways.

Results

Mechanistically, silencing PGAM5 with this nanoplatform precludes the dephosphorylation of Drp1 at Ser637, thereby lessening excessive mitochondrial fission. Yet, it restores the DDX17- BCL6 control mechanism to decrease Drp1 levels, ultimately maintaining mitochondrial balance. CeO2 nanozymes break down reactive oxygen species (ROS), Attenuating cellular oxidative imbalance, while M2 macrophage membranes improve anti-inflammatory targeting to inflamed heart tissue, with PCM ensuring delivery precisely to the heart. In vitro, P-MM@Ps-CeO2 re-established baseline 90% of the viability in lipopolysaccharide- worsened HL-1 cardiomyocytes, attenuated ROS by 70%, and lowered Pro-inflammatory cytokines (IL-1β, TNF-α) by up to 67%. It also preserved mitochondrial integrity, increased ATP production, and lowered apoptosis by 70%. In vivo, in a doxorubicin-induced HF mouse model, the nanoplatform improved ejection fraction to 65% and fractional shortening to 35%, reduced myocardial fibrosis by 30% and apoptosis by 70%, and increased cardiac accumulation by 2.5 times.

Conclusions

These outcomes indicate that P-MM@Ps-CeO₂ transcends conventional HF interventions, which typically fail to address mitochondrial abnormalities. The nanoplatform showed excellent biocompatibility, with minimal hemolytic activity and no detectable organ toxicity, supporting its potential for clinical use. By simultaneously targeting mitochondrial turnover, reactive oxygen species (ROS) stress, and inflammation, P-MM@Ps-CeO2 yields an advantageous pioneering treatment modality, HF, highly capable of improving analysis outcomes for the worldwide HF cohort.

Graphical abstract